J Korean Ophthalmol Soc > Volume 60(6); 2019 > Article
Journal of the Korean Ophthalmological Society 2019;60(6):547-554.
DOI: https://doi.org/10.3341/jkos.2019.60.6.547    Published online June 15, 2019.
Long-term Treatment Outcomes of Intravitreal Bevacizumab Treatment for Myopic Choroidal Neovascularization.
Jeong Min Lee, Jong Woo Kim, Dong Won Lee, Jae Hui Kim
Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. kjh7997@daum.net
근시 맥락막신생혈관에 대한 유리체내 베바시주맙 치료의 장기 결과
건양대학교 의과대학 김안과병원 안과학교실
Correspondence:  Jae Hui Kim,
Email: kjh7997@daum.net
Received: 29 November 2018   • Revised: 3 February 2019   • Accepted: 16 May 2019
To evaluate the long-term treatment outcomes of bevacizumab therapy in patients with myopic choroidal neovascularization (CNV). METHODS: A retrospective review was performed of medical records regarding 43 eyes with myopic CNV that were treated with intravitreal bevacizumab injection. Visual acuity at diagnosis was compared with that measured at the final follow-up; the incidence and timing of re-activation were evaluated. In addition, factors associated with final follow-up were analyzed. RESULTS: Mean patient age was 39.3 ± 12.9 years and mean spherical equivalent (SE) was −11.9 ± 4.4 diopters. Patients were followed-up at a mean of 42.1 ± 17.0 months. Re-activation of the lesion was noted in 17 eyes (39.5%). The mean time to first re-activation was 19.5 ± 15.4 months from the time that resolution of subretinal fluid/retinal fluid was confirmed after initial treatment. The mean visual acuity (the logarithm of the minimal angle of resolution) was 0.40 ± 0.25 at diagnosis and 0.26 ± 0.31 at the final follow-up. Visual acuity at the final follow-up was significantly improved when compared with the baseline value (p = 0.005). Patient age (p < 0.001), SE (p = 0.003), and visual acuity at diagnosis (p < 0.001) were significantly associated with visual acuity at the final follow-up. CONCLUSIONS: Bevacizumab therapy was a useful method for long-term treatment of myopic CNV. The observation of relatively late re-activation after the initial treatment suggests a need for continuous long-term follow-up.
Key Words: Bevacizumab;Choroidal neovascularization;Myopia

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2020 by Korean Ophthalmological Society. All rights reserved.

Developed in M2community

Close layer
prev next